Skip to main content
. 2023 Aug 25;78(1):154–163. doi: 10.1093/cid/ciad501

Figure 3.

Figure 3.

One-way sensitivity analysis on the incremental cost-effectiveness of CRP testing versus no case-finding for tuberculosis in India. Shown is the ICER (x-axis) of screening with CRP test for TB in India, relative to no case-finding, under one-way variation of key model parameters (range given below each parameter, baseline values are presented in Table 1). Parameters for which variation did not change ICER estimates by more than ±10% are not shown. The numbers to the left and right of each bar show the high and low values of the ICER (rounded to 2 significant digits) when varying the respective parameter (blue bars = upper bound of the parameter's range, red bars = lower bound of the parameter's range [there is no lower bound for loss to follow-up, as the loss to follow-up was already at 0% in the baseline model]). The black vertical line specifies the ICER ($1300 per DALY averted in Figure 1) when all parameters are held at their baseline values. The dashed vertical line represents India's willingness-to-pay ($560 per DALY averted). Abbreviations: CRP, C-reactive protein; DALY, disability adjusted life year; ICER, incremental cost-effectiveness ratio; TB, tuberculosis.